Cover Image

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at lea...

Full description

Saved in:
Bibliographic Details
Main Authors: Cross, Nicholas C. P. (Author) , Müller, Martin Christian (Author)
Format: Article (Journal)
Language:English
Published: 05 February 2015
In: Leukemia
Year: 2015, Volume: 29, Issue: 5, Pages: 999-1003
ISSN:1476-5551
DOI:10.1038/leu.2015.29
Online Access:Verlag, Volltext: http://dx.doi.org/10.1038/leu.2015.29
Verlag, Volltext: https://www-nature-com.ezproxy.medma.uni-heidelberg.de/articles/leu201529
Get full text
Author Notes:N.C.P. Cross, H.E. White, D. Colomer, H. Ehrencrona, L. Foroni, E. Gottardi, T. Lange, T. Lion, K. Machova Polakova, S. Dulucq, G. Martinelli, E. Oppliger Leibundgut, N. Pallisgaard, G. Barbany, T. Sacha, R. Talmaci, B. Izzo, G. Saglio, F. Pane, M.C. Müller and A. Hochhaus
Description
Summary:Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has advanced to a stage where many patients achieve very low or undetectable levels of disease. Remarkably, some of these patients remain in sustained remission when treatment is withdrawn, suggesting that they may be at least operationally cured of their disease. Accurate definition of deep molecular responses (MRs) is therefore increasingly important for optimal patient management and comparison of independent data sets. We previously published proposals for broad standardized definitions of MR at different levels of sensitivity. Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants.
Item Description:Gesehen am 29.11.2017
Physical Description:Online Resource
ISSN:1476-5551
DOI:10.1038/leu.2015.29

Similar Items